Certolizumab pegol biosimilar - Xbrane

Drug Profile

Certolizumab pegol biosimilar - Xbrane

Alternative Names: Xcimzane

Latest Information Update: 30 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Xbrane
  • Class Anti-inflammatories; Antirheumatics; Fab fragments; Monoclonal antibodies; Polyethylene glycols
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Ankylosing spondylitis; Crohn's disease; Psoriatic arthritis; Rheumatoid arthritis; Spondylitis

Most Recent Events

  • 30 Oct 2015 Preclinical trials in Ankylosing spondylitis in Sweden (SC)
  • 30 Oct 2015 Preclinical trials in Crohn's disease in Sweden (SC)
  • 30 Oct 2015 Preclinical trials in Psoriatic arthritis in Sweden (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top